Cell Immunotherapy: Principles, Progress, and Challenges

Mingwei Fan

doi:10.54097/2gpqfk55

Authors

Mingwei Fan

DOI:

https://doi.org/10.54097/2gpqfk55

Keywords:

Cell Immunotherapy; Cancer Treatment; CAR-T cells; TCR-T Cells; Immune Checkpoint Inhibitors.

Abstract

Cellular immunotherapy refers to a therapeutic strategy that harnesses the patient's immune system for the purpose of recognizing and eliminating malignant cells. This article provides an overview of the fundamental principles, primary classifications, advancements in clinical implementation, obstacles encountered in practice, as well as potential directions for future development in cellular immunotherapy. Through in-depth analysis, our goal is to delve deeper into the comprehensive knowledge of cellular immunotherapy and look forward to its potential applications in the field of cancer therapy in the future, with a view to opening up new therapeutic avenues.

Downloads

Download data is not yet available.

References

[1] Maude, S.L., et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 2014. 371(16): p. 1507-1517.

[2] Porter, D.L., et al., Chimeric antigen receptor T cells persisting and mediating sustained remissions in multiple myeloma. New England Journal of Medicine, 2015. 373(3): p. 2548-2549.

[3] Schuster, S.J., et al., Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin’s Lymphoma. New England Journal of Medicine, 2017. 377(26): p. 2545-2554.

[4] Davila, M.L., et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 2014. 6(224): p. 224ra25.

[5] Grada, Z. and S.L. Maude, CD19-targeted T cells for the treatment of B cell malignancies. Immunology, 2016. 147(3): p. 369-379.

[6] Ruella, M., et al., Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest, 2016. 126(10): p. 3814-3826.

[7] Shah, N.N., et al., Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med, 2020. 26(10): p. 1569-1575.

[8] Choi, B.D., et al., CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol, 2019. 37(9): p. 1049-1058.

[9] Liao, Q.B., et al., Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res, 2020. 8(1): p. 56.

[10] Fraietta, J.A., et al., Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018. 558(7709): p. 307-312.